Loading...
Market
What will be the outcome of Sage Therapeutics' next major clinical trial by end of 2024?
2
Resolution / Starting Odds
Positive • 25%
Negative • 25%
Inconclusive • 25%
No major trial outcome • 25%
Clinical trial registries and company announcements
Story
Sage and Biogen's SAGE-324 Fails in Mid-Stage Study for Essential Tremor, Stock Drops 25%
Jul 24, 2024, 12:11 PM
Sage Therapeutics and Biogen have announced the topline results from their Phase 2 KINETIC 2 study of SAGE-324 for the treatment of essential tremor. The mid-stage trial did not demonstrate statistically significant differences between any dose of SAGE-324 and placebo in the change from baseline for the primary endpoint. As a result, Biogen and Sage do not plan to conduct further studies for this neurological disorder drug. This failure marks another setback for Biogen's $3 billion alliance with Sage Therapeutics. The experimental pill failed to quell involuntary muscle shaking in patients with essential tremor. Following the announcement, Sage Therapeutics' stock dropped by 25%.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Primary endpoint met • 25%
Primary endpoint not met • 25%
Trial halted due to safety concerns • 25%
Other • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative effects • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results published • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial not completed • 25%
Significant efficacy • 25%
Moderate efficacy • 25%
No efficacy • 25%
Inconclusive results • 25%
Results lead to renewed interest • 25%
Results confirm initial failure • 25%
Mixed reception from the scientific community • 25%
No significant impact • 25%
Study shows significant positive results • 25%
Study shows moderate positive results • 25%
Study shows no significant effect • 25%
Study shows negative results • 25%
Yes • 50%
No • 50%
Successful with measurable cognitive improvement • 25%
Partially successful with some cognitive improvement • 25%
Unsuccessful with no cognitive improvement • 25%
Trial canceled or postponed • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Rejected • 25%
No decision by deadline • 25%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%